Department of Internal Medicine, Saint Louis University School of Medicine, United States.
Division of Endocrinology, Saint Louis University School of Medicine, United States.
Int J Cardiol. 2017 Dec 15;249:319-323. doi: 10.1016/j.ijcard.2017.07.014.
Pheochromocytoma and paraganglioma are rare neuroendocrine tumors which overproduce catecholamines and arise from the adrenal gland or extra-adrenal chromaffin cells of the sympathetic and parasympathetic ganglia (1). Excessive catecholamine-induced stimulation of cardiac myocytes leads to damage which manifests in several forms ranging from Takotsubo to dilated cardiomyopathy. Diagnosis of pheochromocytoma-related cardiomyopathies is often delayed due to the atypical presentation associated with many cases.
Limited data exists on the presentation and outcomes of the various forms of pheochromocytoma-induced cardiomyopathies. We performed a literature review to assess the association of pheochromocytoma and cardiomyopathy to aide in further understanding this clinical entity.
163 cases from 150 articles published between 1991 and November 2016 were included from a PubMed search.
There were 163 occurrences of pheochromocytoma and cardiomyopathy (63 dilated cardiomyopathy, 38 Takotsubo cardiomyopathy, 30 inverted Takotsubo cardiomyopathy, 10 HOCM, 8 myocarditis, and 14 unspecified cardiomyopathy). Many patients lacked classic signs or symptoms of pheochromocytoma with hypertension as a presenting symptom in 65% and the triad of headache, palpitations, and diaphoresis only in 4%. Resection of the pheochromocytoma led to improvement of the cardiomyopathy in 96% while lack of resection was associated with death or cardiac transplantation in 44%.
Pheochromocytoma should be considered in the evaluation of non-ischemic, non-valvular cardiomyopathy even in the absence of symptoms of catecholamine excess. Our study highlights the importance of early suspicion and diagnosis of pheochromocytoma in cases of idiopathic heart failure as early resection may prevent progression to irreversible myocardial remodeling and death.
嗜铬细胞瘤和副神经节瘤是罕见的神经内分泌肿瘤,其过度产生儿茶酚胺,并源自肾上腺或交感和副交感神经节的肾上腺外嗜铬细胞(1)。过量儿茶酚胺诱导的心肌细胞刺激导致损伤,其表现形式多种多样,从 Takotsubo 心肌病到扩张型心肌病。由于许多病例与不典型表现相关,因此嗜铬细胞瘤相关性心肌病的诊断常常被延迟。
嗜铬细胞瘤引起的心肌病的各种形式的表现和结局的相关数据有限。我们进行了文献回顾,以评估嗜铬细胞瘤和心肌病之间的关联,以帮助进一步了解这种临床实体。
从 1991 年至 2016 年 11 月期间发表的 150 篇文章中进行了一项 PubMed 搜索,共纳入 163 例嗜铬细胞瘤和心肌病(63 例扩张型心肌病,38 例 Takotsubo 心肌病,30 例倒置 Takotsubo 心肌病,10 例肥厚型心肌病,8 例心肌炎和 14 例未明确的心肌病)。许多患者缺乏嗜铬细胞瘤的典型体征或症状,高血压是 65%患者的首发症状,而头痛、心悸和出汗三联征仅占 4%。嗜铬细胞瘤切除术可使 96%的心肌病得到改善,而未行切除术的患者中有 44%则与死亡或心脏移植相关。
即使没有儿茶酚胺过多的症状,也应考虑在非缺血性、非瓣膜性心肌病的评估中考虑嗜铬细胞瘤。我们的研究强调了在特发性心力衰竭病例中早期怀疑和诊断嗜铬细胞瘤的重要性,因为早期切除可能防止进展为不可逆的心肌重构和死亡。